St Brendan in Market Wire (press release) Brendan Farrell, Chief Executive Officer of Trinity Biotech, commented, "We are pleased to demonstrate our new high throughput Destiny Max instrument for the haemostasis market in its final design format at the MLTD conference. The instrument is the...